CLC Calculus Vct Plc

RNS No 138m
CLINICAL COMPUTING PLC
17th September 1997
 
Clinical Computing plc
 
Unaudited interim results for six months to 30 June 1997
 
First Half Business Review
 
The Group has produced a profit for the first half of the year
of #0.1m as compared to #0.6m loss for the same period in
1996.  This is the first profitable period recorded by the
Group since its flotation in 1994.  Group turnover in the
first six months of the year rose by 26% to #1.38m compared
with the same period of 1996.  This is the highest first half
turnover that the Group has achieved since it began trading.
 
The Group retains a strong capital base and started the second
half of the year with liquid resources of over #2.0m.  Total
costs for the first half have reduced by 26% compared with the
first half of 1996.  First half maintenance fee income in the
UK has remained steady whilst in the US it has increased by
#77,000
 
 
Highlights
 
The Group has recently introduced a number of new software
products.  The US operation has completed the development of
an all organ transplant clinical management information system
called tx-PROTON.  This product is now available for sale and
we expect to have our first site "go-live" early in 1998.
 
The UK operation has released a clinical management
information system for cancer treatment both by chemotherapy
and radiation therapy, called oc-PROTON.  We are currently
finalising an initial validation contract in the UK for an
oc-PROTON system.
 
We have also completed the development of a Clinical Data
Warehouse (CDW) and it has given us a key competitive
advantage in all multiple facility orders in the US.  CDW is
the Group's first product offering outside of the PROTON
family of products and is based on Oracle databases.
 
In the first half we completed an agreement with Roche
Products Limited to develop a Disease State Management (DSM)
software information system for the transplant speciality. 
DSM will be the only disease management system available in
the market place which is fully integrated with a clinical
management system.  The initial market will be in the UK where
PROTON already has an 85% share of the dialysis market.  A
validation site in the UK for the DSM has now been contracted
and all development will be completed by Q2 1998.  Roche's
sales force will be assisting us with selling and marketing
DSM in the UK and there is a follow-on option for promoting
DSM and di-PROTON world-wide.
 
The US operation acquired the RENLStar product line from
Gambro Healthcare in the second quarter of the year.  The
acquisition has added an additional 150 sites who use the
RENLStar product line to our customer base.  This clearly
makes the Group the leading world-wide provider of software
for the dialysis market place.  Most importantly the
acquisition provides the US operation with an in-house billing
solution which will allow us to be more competitive when
bidding on small to medium tenders.
 
A further benefit is that Gambro Healthcare will provide us
with sales assistance for the development of new business by
referring and recommending di-PROTON to all their customers in
the US, Canada, South America and Central America.
 
Management Changes
 
During the past few years, there has been a substantial
repositioning of the Company's business to take advantage of
the large and growing medical software market in the US.  The
benefits of this hard work and investment are now beginning to
be realised and the management team is in good shape under
Jack Richardson, the Chief Executive.  I believe that now is a
good time for me to step down from the Board to pursue other
business interests.  My board colleagues have elected as
Chairman Michael Gordon to succeed me.

Outlook
 
Clinical Computing has succeeded in turning its business
around and is looking forward to retaining profitability for
the remainder of 1997 and sustaining growth after that.
 
Jeremy Woan
Chairman
 
Clinical Computing Plc
Unaudited Interim Results
Six Months Ended 30 June 1997
 
 
                                6 Months     6 Months     Year
                                 ended         ended     ended
                               30.06.97     30.06.96  31.12.96
                       Notes    #'000        #'000      #'000
 
 
Turnover
- continuing operations         1,376         1,088      1,836
- discontinued operations           0           120        144
                               ------         -----      -----
                                1,376         1,208      1,980
                               ======        ======      =====
 
Operating profit/(loss)
- continuing operations           26          (508)    (1,310) 
- discontinued operations          0          (116)      (800)
                               ------        -------    ------
                                  26          (624)    (2,110)
 
Interest receivable
and similar                       52            25         35
Interest payable
and similar                       0             (2)        (5)
                              -----         -------     ------
Profit/(loss) on ordinary
activities before taxation       78           (601)    (2,080)
 
Taxation                          0              0          0
                              -----          -------    ------
Profit/(loss) attributable
to shareholders                  78           (601)    (2,080)
                              =====          =======   =======
 
Earnings/(loss) per share   3   0.3p          (3.4)p   (12.3)p 
                              =====          =======   =======
 
Notes
 
1.    The unaudited consolidated results for the six months
ended 30 June 1997, set out above have been compiled in
accordance with applicable accounting standards and on a basis
consistent with the annual accounts.  The results for the year
ended 31 December 1996 are an extract from the full accounts
for that year, which received an unqualified report from the
auditors, and which have been filed with the Registrar of
Companies.
 
2.   The unaudited consolidated results for the six months
ended 30 June 1996, set out above, have been restated in
accordance with the Company's change in accounting policy for
recognising software systems revenue.  Full details of this
change in accounting policy are given in the accounts for the
year ended 31 December 1996.
 
3.   The loss per share has been calculated on the basis of
the weighted average number of shares in issue, being
25,080,310 for the six months ended 30 June 1997, 16,612,438 
for the six months ended 30 June 1996 and 16,958,402 for the
year ended 31 December 1996.
 
4.   Copies of this interim report will be sent to
shareholders and are available from the Company's head office
at 414 Chiswick High Road, London W4 5TF.   
 
 
Further information may be obtained from:
 
Clinical Computing plc:                          0181 742 7400
Jack Richardson
 
Henderson Crosthwaite Institutional Brokers Ltd: 0171 623 9992
Andrew Edwards
 
 
 
END

Calculus Vct (LSE:CLC)
Historical Stock Chart
From Jul 2024 to Aug 2024

Calculus Vct (LSE:CLC)
Historical Stock Chart
From Aug 2023 to Aug 2024